Place · Level 3
Thyroid Nodules · this is how the organ is built
甲状腺是几百万个小球堆出来的 · 大脑几十年一直催它长 · 长出来的包九成安静不动 · 神经和甲状旁腺就贴在它背面 · 关键是分层不是别查
Last updated
Story path
- 1An organ built from tiny reservoirsAn organ built from tiny reservoirs
- 2The brain keeps telling it to growThe brain keeps telling it to grow
- 3Why most of them don't moveWhy most of them don't move
- 4Two delicate things on its backTwo delicate things on its back
- 5Stratify — not biopsy on sightStratify — not biopsy on sight
- 6Nodules & iodine · backwardsNodules & iodine · backwards
Chapter 1
An organ built from tiny reservoirs
An organ built from tiny reservoirs
An ultrasound found a thyroid nodule. The most likely explanation isn't that something bad grew in you — it's that the machine finally resolved what this organ has always looked like.
Cut a thyroid open and put it under a microscope and you don't see a solid piece of meat. You see millions of tiny spheres packed together. Each sphere is a follicle, a fraction of a millimeter across, with a structure as simple as a toy: a ring of epithelial cells holding hands to form a shell, with a pool of thick colloid stored in the middle.
That colloid is a warehouse of finished hormone. The thyroid is the only endocrine gland in the body that stores its finished product outside its cells — it builds a large molecule called thyroglobulin, hangs iodine on it, and seals it inside the sphere; when hormone is needed, it chews the molecule back and cuts thyroid hormone loose into the blood. That warehouse holds enough for two to three months (Zimmermann 2009).
So structurally, this organ is a heap of tiny reservoirs. Its building block isn't a fiber or a tube. It's a sphere. Everything downstream follows from that.
Now put that next to the probe. Follicles live at the fraction-of-a-millimeter scale; when a patch of follicles grows a little harder than its neighbors, the bulge it makes is one, two, a few millimeters across. And the high-frequency ultrasound probe in today's check-up rooms happens to resolve exactly that scale.
One German group drew the line bluntly: earlier work with a 7.5 MHz probe reported nodules in 33% of people; a later group scanned 635 check-up patients with a sharper 13 MHz probe and found nodules in 68% (Guth 2009). Those are two different groups in two different studies, not one group rescanned, so strictly it can't rule out the groups simply differing. But the direction is plain: once the ruler gets as fine as the organ's own building block, you start seeing the organ's grain.
That isn't more disease. That's resolution catching up with anatomy.
The same logic holds on the autopsy table: when pathologists section a thyroid finely enough, they find plenty of tiny foci in people never diagnosed in life — and that detection rate has not risen in sixty years (Harach 1985; Furuya-Kanamori 2016). The numbers are on the page below; the conclusion is one line — the finer you look, the more you find.
Hold onto it. The next five scenes are all its corollaries: finding it doesn't mean it was ever going to hurt you.
Cut a thyroid open and put it under a microscope and you don't see a solid piece of meat. You see millions of tiny spheres packed together. Each sphere is a follicle, a fraction of a millimeter across, with a structure as simple as a toy: a ring of epithelial cells holding hands to form a shell, with a pool of thick colloid stored in the middle.
That colloid is a warehouse of finished hormone. The thyroid is the only endocrine gland in the body that stores its finished product outside its cells — it builds a large molecule called thyroglobulin, hangs iodine on it, and seals it inside the sphere; when hormone is needed, it chews the molecule back and cuts thyroid hormone loose into the blood. That warehouse holds enough for two to three months (Zimmermann 2009).
So structurally, this organ is a heap of tiny reservoirs. Its building block isn't a fiber or a tube. It's a sphere. Everything downstream follows from that.
Now put that next to the probe. Follicles live at the fraction-of-a-millimeter scale; when a patch of follicles grows a little harder than its neighbors, the bulge it makes is one, two, a few millimeters across. And the high-frequency ultrasound probe in today's check-up rooms happens to resolve exactly that scale.
One German group drew the line bluntly: earlier work with a 7.5 MHz probe reported nodules in 33% of people; a later group scanned 635 check-up patients with a sharper 13 MHz probe and found nodules in 68% (Guth 2009). Those are two different groups in two different studies, not one group rescanned, so strictly it can't rule out the groups simply differing. But the direction is plain: once the ruler gets as fine as the organ's own building block, you start seeing the organ's grain.
That isn't more disease. That's resolution catching up with anatomy.
The same logic holds on the autopsy table: when pathologists section a thyroid finely enough, they find plenty of tiny foci in people never diagnosed in life — and that detection rate has not risen in sixty years (Harach 1985; Furuya-Kanamori 2016). The numbers are on the page below; the conclusion is one line — the finer you look, the more you find.
Hold onto it. The next five scenes are all its corollaries: finding it doesn't mean it was ever going to hurt you.
数字 · 尺子换细了, 检出的就翻倍
把探头的分辨率和检出率放在一起看, 这条线很直白。德国那组研究: 早年用 7.5 兆赫的探头查, 报告的结节检出率是 33%; 后来有人用看得更清楚的 13 兆赫探头查了 635 个体检者, 68% 的人身上找得到结节 (Guth 2009)。
这是两批人、两项研究, 不是同一批人换了台机器, 严格说不能排除人群本身不一样。但方向很清楚: 这不是病变变多了, 是分辨率追上了解剖。
同一条道理在解剖台上也成立: 病理科医生把甲状腺切得足够细的时候, 能在生前从没被诊断过的人身上找到大量微小病灶, 而这个检出率六十年来并没有上升 (Harach 1985; Furuya-Kanamori 2016)。结论只有一句——找得越细, 找到的越多。
Background · what autopsies find
This page is background, not this story's argument. The argument is in the main text: this organ is natively a heap of millimeter-scale spheres. Autopsy data only confirms the same thing from another direction.Finland (Harach 1985): 101 consecutive autopsies, thyroids subserially sectioned at 2-3 mm. Fifty-two occult papillary carcinoma foci were found across 36 glands — a 35.6% detection rate, the highest reported anywhere at the time. Tumor diameter ranged from 0.15 mm to 14 mm, with 67% under 1 mm. The authors titled the paper accordingly: in Finland, this is a normal finding.
Six-decade pooled analysis (Furuya-Kanamori 2016): 35 studies, 12,834 autopsies. Stratified by examination intensity:
Whole gland examined: 11.2% (95% CI 6.7-16.1%)Partial sampling only: 4.1% (95% CI 3.0-5.4%)
The same pooled analysis found that the autopsy detection rate has not risen over six decades.
Why is Finland 35.6% and the pooled figure only 11.2%? Because Finland's section interval (2-3 mm) was far finer than most studies. Notice the coincidence: the blade's interval is in millimeters, and the probe's resolution is in millimeters — both rulers are graduated at exactly the scale at which a patch of follicles bulges into a lump, so they are seeing the same thing.
In other words, a detection rate is a number about your method, not about the disease. And the reason a method can move it at all is the anatomical fact in the main text: this organ's grain sits at the millimeter scale to begin with.
Chapter 2
The brain keeps telling it to grow
The brain keeps telling it to grow
Your thyroid hasn't taken a day off since you were born — and something has been prodding it the whole time. After a few decades of prodding, an organ that grew unevenly is the most ordinary outcome there is.
The thyroid doesn't decide its own workload. The pituitary, at the base of your brain, does. The pituitary constantly tastes the thyroid hormone level in your blood, and when it runs low it releases thyroid-stimulating hormone (thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive.).
TSH drifts down the bloodstream to your neck and parks on the receiving ports on the surface of follicle cells. That docking does three things at once:
Tells the cell to grab iodine out of the bloodTells the cell to chew the colloid back out of the sphere and cut hormone loose into the bloodTells the cell to get taller and to multiply — that is, to proliferate
The first two are today's work. The third is the long-run account: TSH isn't only a throttle, it is also a growth signal. When blood hormone is adequate, the pituitary lifts its foot; when it isn't, the foot stays down.
When iodine is short, that foot never comes up. Not enough raw material, not enough hormone; not enough hormone, so the pituitary keeps releasing TSH; TSH keeps coming, so follicle cells are driven to proliferate year after year, and the whole gland enlarges — that is goiter (Zimmermann 2009).
The key is the next step. The same dose of TSH lands on millions of follicles, and they do not respond alike. Follicles carry innate differences: some are sensitive to TSH and grow eagerly; others barely bother. Over one year the difference is invisible. Over ten years, thirty years, the leaders pull further and further ahead — from a speck only a microscope could see into a lump you can feel and scan.
That is where a nodule comes from. Nothing burrowed in from outside. It is your own follicles, grown uneven after decades of prodding.
So two facts that used to be puzzling need no statistics to explain:
Why are nodules so common? Because everyone's thyroid is being prodded, without a break, for life.Why do they multiply with age? Because the longer the prodding runs, the wider the gap opens.
A nodule you can feel or scan has, as its default explanation, this organ's normal way of working — not something in there killing you.
The thyroid doesn't decide its own workload. The pituitary, at the base of your brain, does. The pituitary constantly tastes the thyroid hormone level in your blood, and when it runs low it releases thyroid-stimulating hormone (thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive.).
TSH drifts down the bloodstream to your neck and parks on the receiving ports on the surface of follicle cells. That docking does three things at once:
Tells the cell to grab iodine out of the bloodTells the cell to chew the colloid back out of the sphere and cut hormone loose into the bloodTells the cell to get taller and to multiply — that is, to proliferate
The first two are today's work. The third is the long-run account: TSH isn't only a throttle, it is also a growth signal. When blood hormone is adequate, the pituitary lifts its foot; when it isn't, the foot stays down.
When iodine is short, that foot never comes up. Not enough raw material, not enough hormone; not enough hormone, so the pituitary keeps releasing TSH; TSH keeps coming, so follicle cells are driven to proliferate year after year, and the whole gland enlarges — that is goiter (Zimmermann 2009).
The key is the next step. The same dose of TSH lands on millions of follicles, and they do not respond alike. Follicles carry innate differences: some are sensitive to TSH and grow eagerly; others barely bother. Over one year the difference is invisible. Over ten years, thirty years, the leaders pull further and further ahead — from a speck only a microscope could see into a lump you can feel and scan.
That is where a nodule comes from. Nothing burrowed in from outside. It is your own follicles, grown uneven after decades of prodding.
So two facts that used to be puzzling need no statistics to explain:
Why are nodules so common? Because everyone's thyroid is being prodded, without a break, for life.Why do they multiply with age? Because the longer the prodding runs, the wider the gap opens.
A nodule you can feel or scan has, as its default explanation, this organ's normal way of working — not something in there killing you.
机制 · 缺碘时那脚油门为什么松不开
血里激素够了, 垂体就松脚; 不够, 它就一直踩着。碘不够的时候, 这脚油门就松不开。原料不足, 激素造不够; 激素造不够, 垂体就一直放 thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive.; TSH 一直放, 滤泡细胞就被长年累月地催着增生, 整个腺体跟着变大——这就是甲状腺肿 (Zimmermann 2009)。
而滤泡之间天生带着差异: 有的对 TSH 敏感, 一催就长; 有的不太理会。所以两件本来让人困惑的事, 到这里都不需要统计学来解释:
结节为什么这么常见? 因为每个人的甲状腺都在被催, 一辈子没停过。为什么年纪越大越多? 因为催的时间越长, 差距拉得越开。
一个能摸到、能照到的结节, 它的默认解释是这个器官的正常工作方式, 不是有东西在杀你。
Mechanism · why many, not one
The word *multi* in the diagnosis multinodular goiter is a direct consequence of the heterogeneity in the main text. If every follicle answers thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. differently, then after decades of prodding what surfaces is never one lump but a batch of them, in assorted sizes.Autonomous nodules, also called hot nodules: as they grow, some nodules simply stop taking orders from TSH and make hormone at their own pace. This is especially common in regions with long-standing iodine deficiency — decades of prodding accumulate a set of unsupervised workshops.
Those workshops produce a counterintuitive consequence: when iodine is restored to a long-deficient population, a transient wave of hyperthyroidism appears — iodine-induced hyperthyroidism. The unsupervised nodules suddenly receive ample raw material, run flat out, and overproduce hormone (Zimmermann 2009). This is part of the right-hand half of scene 6's U-shaped curve; remember it, you'll need it there.
So could you run it backwards — suppress TSH and shrink the nodule? It's a natural thought: if TSH is the growth signal, cut the signal. That road was tried and rejected. Guidelines explicitly advise against levothyroxine TSH suppression for benign nodules in iodine-sufficient populations, because the benefit doesn't cover the cost — to hold down a lump that most likely won't harm you, you soak your whole body in mild thyrotoxicosis for years, buying arrhythmia and bone-loss risk (ATA 2015 / Haugen 2016).
Mechanistically coherent is not the same as clinically worth it. This site will keep coming back to that.
Chapter 3
Why most of them don't move
Why most of them don't move
The small things inside the thyroid mostly sit still for a lifetime. That isn't reassurance — people actually watched, and measured, year after year.
Start with why they can be so quiet. The last scene said a nodule is just follicles that grew eagerly; and the cancer that arises from follicular epithelium is classified, in pathology, as differentiated thyroid cancer. Differentiated means it still looks a lot like the follicle cell it came from and still does the old job — still takes up iodine, still makes thyroglobulin, still listens to thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive.. A cell that keeps showing up for its day job divides slowly and isn't much good at escaping. It is a different species from the cancer that has entirely forgotten who it is (that one is in scene 6, and it is savage).
This isn't armchair reasoning; someone spent decades testing it. From 1993, Kuma Hospital in Japan did something brave: it offered patients with low-risk papillary microcarcinoma an extra option — don't cut, just watch with periodic ultrasound. This is active surveillance. The low-risk bar is explicit: no more than 1 cm across, not growing outside the capsule, no lymph node metastasis, and not sitting against the trachea or the recurrent laryngeal nerve.
1,235 people were watched this way for years, and the results were (Ito 2014):
Tumors that grew by 3 mm or more: 4.9% at 5 years; 8.0% at 10 yearsNew lymph node metastases at 5 / 10 years: 1.7% / 3.8%Across the whole program, nobody developed distant metastasis and nobody died of thyroid carcinoma
Over ten years, more than nine in ten didn't budge. And for the under-one-in-ten that did grow, operating once it grew was still in time — the group converted to delayed surgery had no life-threatening recurrences.
Read this part slowly: active surveillance isn't a gamble and it isn't giving up on treatment. It is saving the operation for when it's needed.
And the reason it's possible is, again, anatomy. The thyroid sits right under the skin at the front of your neck, where an ultrasound sees it clearly through one layer of tissue, remeasurable whenever you like. It's one of the few organs in the body that can be watched this closely — the pancreas and the ovaries, buried deep in the abdomen, get no such courtesy.
Start with why they can be so quiet. The last scene said a nodule is just follicles that grew eagerly; and the cancer that arises from follicular epithelium is classified, in pathology, as differentiated thyroid cancer. Differentiated means it still looks a lot like the follicle cell it came from and still does the old job — still takes up iodine, still makes thyroglobulin, still listens to thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive.. A cell that keeps showing up for its day job divides slowly and isn't much good at escaping. It is a different species from the cancer that has entirely forgotten who it is (that one is in scene 6, and it is savage).
This isn't armchair reasoning; someone spent decades testing it. From 1993, Kuma Hospital in Japan did something brave: it offered patients with low-risk papillary microcarcinoma an extra option — don't cut, just watch with periodic ultrasound. This is active surveillance. The low-risk bar is explicit: no more than 1 cm across, not growing outside the capsule, no lymph node metastasis, and not sitting against the trachea or the recurrent laryngeal nerve.
1,235 people were watched this way for years, and the results were (Ito 2014):
Tumors that grew by 3 mm or more: 4.9% at 5 years; 8.0% at 10 yearsNew lymph node metastases at 5 / 10 years: 1.7% / 3.8%Across the whole program, nobody developed distant metastasis and nobody died of thyroid carcinoma
Over ten years, more than nine in ten didn't budge. And for the under-one-in-ten that did grow, operating once it grew was still in time — the group converted to delayed surgery had no life-threatening recurrences.
Read this part slowly: active surveillance isn't a gamble and it isn't giving up on treatment. It is saving the operation for when it's needed.
And the reason it's possible is, again, anatomy. The thyroid sits right under the skin at the front of your neck, where an ultrasound sees it clearly through one layer of tissue, remeasurable whenever you like. It's one of the few organs in the body that can be watched this closely — the pancreas and the ovaries, buried deep in the abdomen, get no such courtesy.
临床 · 有人真的这样盯了很多年
这不是纸上推理, 有人真的用几十年去验证。日本 Kuma 医院从 1993 年起做了一件很有勇气的事: 对低危微小乳头状癌的患者, 提供一个额外的选项——先不切, 定期做超声看着, 也就是主动监测 (active surveillance)。低危的门槛很明确: 直径不超过 1 厘米、没长到包膜外面、没有淋巴结转移、也没有贴着气管或喉返神经。1235 个人这样被看了很多年, 结果是 (Ito 2014):
5 年里肿瘤长大 3 毫米以上的, 占 4.9%; 10 年是 8.0%5 年 / 10 年里新出现淋巴结转移的, 是 1.7% / 3.8%整个过程中, 没有一个人出现远处转移, 没有一个人死于甲状腺癌
十年里九成以上纹丝不动。而那不到一成真的长了的, 等它长了再去手术, 一样来得及——转去做延迟手术的那批人, 没有出现威胁生命的复发。
Chapter 4
Two delicate things on its back
Two delicate things on its back
Just cut it out for peace of mind. It sounds like a bargain, because it quietly prices the cost at zero. The cost is not zero, and the reason is written in the anatomy: pressed against the back of the thyroid are two structures that matter enormously and are very hard to avoid.
First, to be clear: this scene blames no one. Many people have already had the surgery, and under the consensus of the time their doctors' advice was entirely reasonable. The point isn't that you shouldn't have had it — it's why this bill can never be zero, so that people who haven't reached this fork can weigh both sides on the same scale.
The first is the recurrent laryngeal nerve. It works the opening and closing of your two vocal cords. Its route is absurd: it runs down through the neck, loops under the great vessels at the top of the chest, then turns back upward (recurrent means exactly that — it comes back). And the stretch where it climbs back up runs in the groove between the trachea and the esophagus, with the back of the thyroid pressed against the outside of that groove. Which means: to lift the thyroid out of that position, you must cut right beside this nerve. Bruise it and that vocal cord stops moving properly and the voice goes hoarse; injure both sides and breathing is compromised.
The second is the parathyroid glands. Four of them, each the size of a grain of rice, stuck to the back of the thyroid. Their job is not small: the calcium level in your blood is theirs to guard. The trouble is that they are tiny, they look much like the surrounding fat, and their blood comes through fine vessels branching off the thyroid's own supply. So the surgical risk isn't only cutting one out — more often it's severing those fine vessels while dissecting the thyroid away. The gland is still there; it's just starving. When it stops working, blood calcium falls and your hands and feet start to go numb and cramp.
Those two facts are the anatomical explanation of the bill. Why are the signature complications of thyroid surgery a hoarse voice and numb hands? Not because surgeons are careless — because the back of this organ is built that way. Every dissection happens right next to those two things.
One more unavoidable line item: after part or all of the thyroid is removed, the remaining tissue may not supply the hormone you need, so a daily tablet makes up the difference. That isn't a complication, it's arithmetic — you removed part of scene 1's warehouse yourself.
The numbers are on the page below. One note first: those complication rates come from Kuma Hospital in Japan, one of the highest-volume, best centers in the world for this operation. An ordinary hospital only looks worse (Adam 2017).
First, to be clear: this scene blames no one. Many people have already had the surgery, and under the consensus of the time their doctors' advice was entirely reasonable. The point isn't that you shouldn't have had it — it's why this bill can never be zero, so that people who haven't reached this fork can weigh both sides on the same scale.
The first is the recurrent laryngeal nerve. It works the opening and closing of your two vocal cords. Its route is absurd: it runs down through the neck, loops under the great vessels at the top of the chest, then turns back upward (recurrent means exactly that — it comes back). And the stretch where it climbs back up runs in the groove between the trachea and the esophagus, with the back of the thyroid pressed against the outside of that groove. Which means: to lift the thyroid out of that position, you must cut right beside this nerve. Bruise it and that vocal cord stops moving properly and the voice goes hoarse; injure both sides and breathing is compromised.
The second is the parathyroid glands. Four of them, each the size of a grain of rice, stuck to the back of the thyroid. Their job is not small: the calcium level in your blood is theirs to guard. The trouble is that they are tiny, they look much like the surrounding fat, and their blood comes through fine vessels branching off the thyroid's own supply. So the surgical risk isn't only cutting one out — more often it's severing those fine vessels while dissecting the thyroid away. The gland is still there; it's just starving. When it stops working, blood calcium falls and your hands and feet start to go numb and cramp.
Those two facts are the anatomical explanation of the bill. Why are the signature complications of thyroid surgery a hoarse voice and numb hands? Not because surgeons are careless — because the back of this organ is built that way. Every dissection happens right next to those two things.
One more unavoidable line item: after part or all of the thyroid is removed, the remaining tissue may not supply the hormone you need, so a daily tablet makes up the difference. That isn't a complication, it's arithmetic — you removed part of scene 1's warehouse yourself.
The numbers are on the page below. One note first: those complication rates come from Kuma Hospital in Japan, one of the highest-volume, best centers in the world for this operation. An ordinary hospital only looks worse (Adam 2017).
背景 · 这不是在指责谁, 是在算账
先说清楚: 这不是要指责任何人。很多人已经做完了手术, 而在当时的共识下, 医生给的建议完全合理。这里要讲的不是你不该切, 而是这笔账为什么一定不是零——好让还没走到这一步的人, 能把两边放在同一个天平上称。喉返神经两边都伤到, 会喘不上气; 这是最重的那一档。
还有一样跑不掉的账: 甲状腺被切掉一部分或全部之后, 剩下的组织未必供得上你需要的激素量, 于是要靠每天一片药补回来。这不算并发症, 这是算术——那个激素仓库, 你亲手拆掉了一部分。
下一页那组并发症率来自日本 Kuma 医院, 全世界做这台手术做得最多、最好的中心之一。换到普通医院只会更难看 (Adam 2017)。
Clinical · the bill, surgery vs surveillance
Same hospital, same low-risk microcarcinomas, immediate surgery next to active surveillance (Oda 2016):Needing lifelong levothyroxine: 66.1% vs 20.7%Transient hypoparathyroidism (numb hands and feet, cramping): 16.7% vs 2.8%Permanent hypoparathyroidism: 1.6% vs 0.08%Transient vocal cord paralysis (voice goes hoarse): 4.1% vs 0.6%Permanent vocal cord paralysis: 0.2% in the surgery group, 0 in surveillance
Map these rows onto the anatomy in the main text: the two parathyroid rows are the four rice grains on the back being injured or starved during dissection; the two vocal-cord rows are the nerve climbing back up the tracheoesophageal groove. The menu of complications is set by anatomy — it isn't random bad luck.
Removing only half isn't free either: after hemithyroidectomy, 26.4% of 535 patients ultimately still needed levothyroxine (Ahn 2019). The remaining lobe doesn't always cover it.
Whether the operator does this often matters, concretely: US data show that the lower a surgeon's annual volume, the higher the patient's complication rate — a relationship that continues up to roughly 26 cases per year (Adam 2017). So the numbers above, from an ultra-high-volume center like Kuma, represent this operation's ceiling performance, not its average.
And one line item that never appears on a consent form. Once the word cancer is attached to you it doesn't peel off: in US data, thyroid cancer survivors report psychological financial hardship at nearly twice the rate of other cancer survivors (46.1% vs 24.0%, Barrows 2020). Insurance, mortgages, work, and the few days before every follow-up scan are all in that account.
ahn-2019-levothyroxine-hemithyroidectomybarrows-2020-thyroid-cancer-financial-burden
Chapter 5
Stratify — not biopsy on sight
Stratify — not biopsy on sight
Those words on your ultrasound report — hypoechoic, microcalcification, taller-than-wide — aren't mystical scoring. Behind each of them is a specific tissue appearance under the microscope. What the radiologist is doing is reading histology through your skin.
The first four scenes told you: this organ is natively a heap of spheres (scene 1), prodded into growing unevenly (scene 2), and what grows mostly keeps doing its day job (scene 3), while acting on it carries an anatomical cost (scene 4). Add those up and you don't get *don't look*. You get: we need a way to guess what the cells inside this lump look like, without cutting it open.
That way is ultrasound. It reads echo — sound goes in, and different things bounce back with different strength. Different tissue appearance, different reflection. So every sonographic feature is an indirect answer to a histological question:
Cystic or spongiform points benign. A lump that looks like a cluster of little bubbles looks that way because that's what it is: swollen follicles, still holding colloid in their centers. Fluid barely blocks sound, so it reads bright. It's scene 1's normal structure, enlarged but not distorted.Solid and hypoechoic (dark on the image) points suspicious. To reflect sound you need interfaces. A dark lump means the cells inside are packed shoulder to shoulder with no colloid and no fluid — the warehouse in the center is gone, and the cells only grow, no longer doing the job of storing hormone. That is what *stopped showing up for work* looks like on ultrasound.Microcalcifications (specks of white) are the most telling one. These pinpoint bright foci often correspond to psammoma bodies under the microscope: concentric little spheres laid down layer by layer as cells that died inside a papillary carcinoma calcify, only tens of micrometers across (Tessler 2017). Benign colloid nodules don't make them. So a scatter of white specks doesn't mean the lump is hard — it means a batch of those cells died in there.Taller-than-wide points suspicious. A benign nodule grows passively: it pushes along the grain of the surrounding tissue, toward least resistance, and gets squashed into a flat, lying-down shape. A malignant one ignores the grain and grows across tissue planes, so on the image it stands up. Its shape isn't merely odd — it isn't obeying the constraints of the tissue around it.Ill-defined or lobulated margins, or growth beyond the gland, points suspicious. A benign nodule usually shuts itself inside a capsule, with a smooth border. A ragged, lobulated margin means it is infiltrating outward with no wall around it.
Once you see this layer, the TI-RADS scoring table (on the page below) stops being a pile of points: it is those five histological questions, asked one at a time, with the answers added up (Tessler 2017).
Only after grading does fine-needle aspiration (FNA) come up. Here's the key: the biopsy threshold depends on grade and size together — the lower the grade, the bigger it has to be. An 8 mm nodule that looks entirely well-behaved does not get biopsied under the rules.
That isn't laziness and it isn't cost-cutting. Back to scenes 1 and 2: biopsying it will most likely find something this organ has always had, and then put you on scene 4's operating table.
So *any nodule means biopsy* is wrong. But so is the reverse: *I have a nodule, so I'll ignore it*. The rules are the rules: follow up what needs following, biopsy what needs biopsy, remove what needs removing. Stratification means sending each nodule down the path it belongs on, not sending all of them down the same one.
The first four scenes told you: this organ is natively a heap of spheres (scene 1), prodded into growing unevenly (scene 2), and what grows mostly keeps doing its day job (scene 3), while acting on it carries an anatomical cost (scene 4). Add those up and you don't get *don't look*. You get: we need a way to guess what the cells inside this lump look like, without cutting it open.
That way is ultrasound. It reads echo — sound goes in, and different things bounce back with different strength. Different tissue appearance, different reflection. So every sonographic feature is an indirect answer to a histological question:
Cystic or spongiform points benign. A lump that looks like a cluster of little bubbles looks that way because that's what it is: swollen follicles, still holding colloid in their centers. Fluid barely blocks sound, so it reads bright. It's scene 1's normal structure, enlarged but not distorted.Solid and hypoechoic (dark on the image) points suspicious. To reflect sound you need interfaces. A dark lump means the cells inside are packed shoulder to shoulder with no colloid and no fluid — the warehouse in the center is gone, and the cells only grow, no longer doing the job of storing hormone. That is what *stopped showing up for work* looks like on ultrasound.Microcalcifications (specks of white) are the most telling one. These pinpoint bright foci often correspond to psammoma bodies under the microscope: concentric little spheres laid down layer by layer as cells that died inside a papillary carcinoma calcify, only tens of micrometers across (Tessler 2017). Benign colloid nodules don't make them. So a scatter of white specks doesn't mean the lump is hard — it means a batch of those cells died in there.Taller-than-wide points suspicious. A benign nodule grows passively: it pushes along the grain of the surrounding tissue, toward least resistance, and gets squashed into a flat, lying-down shape. A malignant one ignores the grain and grows across tissue planes, so on the image it stands up. Its shape isn't merely odd — it isn't obeying the constraints of the tissue around it.Ill-defined or lobulated margins, or growth beyond the gland, points suspicious. A benign nodule usually shuts itself inside a capsule, with a smooth border. A ragged, lobulated margin means it is infiltrating outward with no wall around it.
Once you see this layer, the TI-RADS scoring table (on the page below) stops being a pile of points: it is those five histological questions, asked one at a time, with the answers added up (Tessler 2017).
Only after grading does fine-needle aspiration (FNA) come up. Here's the key: the biopsy threshold depends on grade and size together — the lower the grade, the bigger it has to be. An 8 mm nodule that looks entirely well-behaved does not get biopsied under the rules.
That isn't laziness and it isn't cost-cutting. Back to scenes 1 and 2: biopsying it will most likely find something this organ has always had, and then put you on scene 4's operating table.
So *any nodule means biopsy* is wrong. But so is the reverse: *I have a nodule, so I'll ignore it*. The rules are the rules: follow up what needs following, biopsy what needs biopsy, remove what needs removing. Stratification means sending each nodule down the path it belongs on, not sending all of them down the same one.
机制 · 五条超声特征各在问什么
这个器官本来就是一堆球, 被催着长得不整齐, 长出来的东西大多还守着本职工作, 而动它是有解剖代价的。四件事合起来, 得到的不是别查, 而是: 得有一套办法, 在不切开的前提下, 猜出这个包里的细胞长什么样。超声就是这套办法, 而每一条超声特征, 都是一个组织学问题的间接答案:囊性或海绵样, 指向良性。 一个包看着像一堆小水泡挤在一起, 是因为它里面就是一堆胀大的滤泡, 球心里装的还是那汪胶质。液体不太挡声波, 图上就亮。它是那个正常结构的放大版, 没走样。实性加低回声 (图上发暗), 指向可疑。 声波要反射, 得有界面。一个包发暗, 说明里面细胞挨得密密麻麻, 没有胶质、没有水——球心那汪仓库不见了, 细胞只顾自己长, 不再干储存激素的活。微钙化 (一粒粒白点), 是最要紧的一条。 这些针尖大的强回声点, 对应的往往是显微镜下的砂粒体: 乳头状癌里死掉的细胞钙化之后, 一层层裹成的同心圆小体, 只有几十微米大 (Tessler 2017)。良性的胶质结节不造这个。所以看到一片白点, 意思不是这个包硬, 而是这个包里死过一批那种细胞。纵横比大于 1 (立着长), 指向可疑。 良性结节是被动长大的: 它顺着周围组织的纹理, 往阻力小的方向推, 于是被挤成一个扁的、躺着的形状。恶性的不管纹理, 横着穿过组织平面往外长, 在图上就显得立着。它不是形状怪, 是它不服从周围组织的约束。边界模糊、分叶、或者长到腺体外面, 指向可疑。 良性结节通常有一圈包膜把自己关起来, 边界光滑。边界毛糙、分叶, 说明它在往周围浸润, 身上没有围墙。
规矩就是规矩: 该随访的随访, 该穿的穿, 该切的切。
Clinical · TI-RADS and FNA thresholds
TI-RADS stands for Thyroid Imaging Reporting and Data System. Below is the American College of Radiology (ACR) 2017 version (Tessler 2017), placed here so you can read it against your own report. The main text already covered the histology behind each feature; this page only turns them into points.Five scored feature categories:
1. Composition: cystic / spongiform / mixed / solid (solid scores highest)
2. Echogenicity: anechoic / hyper- or isoechoic / hypoechoic / very hypoechoic (darker scores higher)
3. Shape: wider-than-tall / taller-than-wide (standing up scores higher)
4. Margin: smooth / ill-defined / lobulated or irregular / extra-thyroidal extension
5. Echogenic foci: none / large comet-tail / macrocalcification / peripheral rim / punctate echogenic foci (microcalcification)
Sum the five scores to get a level, then combine with maximum diameter to decide the action:
| Level | Points | Malignancy risk | FNA threshold | Follow-up threshold |
|---|---|---|---|---|
| TR1 benign | 0 | ~0.3% | none | none |
| TR2 not suspicious | 1-2 | ~1.5% | none | none |
| TR3 mildly suspicious | 3 | ~4.8% | ≥ 2.5 cm | ≥ 1.5 cm |
| TR4 moderately suspicious | 4-6 | ~9.1% | ≥ 1.5 cm | ≥ 1.0 cm |
| TR5 highly suspicious | ≥ 7 | ~35% | ≥ 1.0 cm | ≥ 0.5 cm |
The thing to catch in this table is the diagonal: at the same size, the more suspicious it looks, the lower the threshold; at the same appearance, the smaller it is, the more you leave it alone. A 1.2 cm TR3 doesn't get biopsied; a 1.2 cm TR5 does. Size alone is never the reason — size plus appearance is.
Two more things worth knowing:
The American Thyroid Association (ATA) 2015 guidelines are a parallel stratification scheme (Haugen 2016) with the same logic and slightly different thresholds. Which one your report uses depends on the hospital.TI-RADS is a communication and triage tool, not a diagnosis. It gives a probability and a next action, not a conclusion. The real conclusion comes from biopsy cytology, plus you and your doctor weighing your age, family history, symptoms, and how much the uncertainty costs you.
This page is here to help you read your report, not to grade yourself. Executing the stratification is the clinician's job.
Chapter 6
Nodules & iodine · backwards
Nodules & iodine · backwards
If you have a nodule you must avoid iodine, switch to non-iodized salt, and never eat kelp or nori — this is the most widely repeated thyroid claim on the Chinese internet, and it has the direction backwards.
You already know where it goes wrong, from scene 2: iodine is the raw material, and the direct consequence of short raw material is a pituitary with its foot on the throttle. Not enough iodine, not enough hormone; not enough hormone, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. keeps coming; TSH keeps coming, follicles are driven to proliferate, and over years they grow into nodules (Zimmermann 2009). Iodine deficiency is itself a classic cause of nodular goiter — that chain is textbook causation, not correlation.
So a person who already has a nodule and deliberately avoids iodine is doing something deeply ironic: in order to shrink the nodule, they press the throttle down harder with their own hand.
The data agree. Pool 25 studies and over 50,000 people: those with urinary iodine below 100 µg/L have roughly 30% higher nodule risk than iodine-replete people. But look at the other end of the curve too: run the continuous dose-response and the whole relationship is a statistically significant U-shape (P for nonlinearity < 0.001) — risk rises at both the deficient and the excessive end, with the low point around 221 µg/L (Lu 2026, pooled cross-sectional, association not causation).
The right-hand half of the U has a mechanism too, and scene 2's page already planted it: when iodine is abundant, the autonomous nodules that no longer take orders from TSH suddenly receive ample raw material and run flat out (Zimmermann 2009). So neither end is good — it is not *less is safer*, and it is not *more is better*. The full iodine-thyroid U-curve is taught in detail on the iodine island, and the kelp story has a dedicated animation for it; go there rather than have it repeated here.
This story adds only the conclusion: your nodule almost certainly wasn't caused by iodine, and won't be dissolved by avoiding it. It is most likely what scenes 1 and 2 described — your own follicles, prodded for decades, grown uneven, and then lit up by an ultrasound with enough resolution to see them.
There are two genuine exceptions who should discuss iodine with a doctor individually: people who already test positive for Hashimoto's antibodies (details on the Hashimoto island), and people facing iodine contrast imaging or with existing hyperthyroidism.
Finally, be clear where this story lands. It does not tell you don't get checked. It tells you stratify. Anyone with a nodule should follow their own doctor and guideline-based management. This page is education about why the rules look the way they do — it is not medical advice.
See a doctor promptly, don't wait, for any of these: a persistently hoarse voice; new difficulty swallowing or breathing; a nodule that visibly enlarges over a short period; something that feels hard and fixed in place; enlarged lymph nodes in the neck; a childhood history of head-and-neck radiation; or a first-degree relative with thyroid cancer. These are signals that genuinely need pursuing — an entirely different thing from a small nodule an ultrasound stumbled onto.
You already know where it goes wrong, from scene 2: iodine is the raw material, and the direct consequence of short raw material is a pituitary with its foot on the throttle. Not enough iodine, not enough hormone; not enough hormone, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. keeps coming; TSH keeps coming, follicles are driven to proliferate, and over years they grow into nodules (Zimmermann 2009). Iodine deficiency is itself a classic cause of nodular goiter — that chain is textbook causation, not correlation.
So a person who already has a nodule and deliberately avoids iodine is doing something deeply ironic: in order to shrink the nodule, they press the throttle down harder with their own hand.
The data agree. Pool 25 studies and over 50,000 people: those with urinary iodine below 100 µg/L have roughly 30% higher nodule risk than iodine-replete people. But look at the other end of the curve too: run the continuous dose-response and the whole relationship is a statistically significant U-shape (P for nonlinearity < 0.001) — risk rises at both the deficient and the excessive end, with the low point around 221 µg/L (Lu 2026, pooled cross-sectional, association not causation).
The right-hand half of the U has a mechanism too, and scene 2's page already planted it: when iodine is abundant, the autonomous nodules that no longer take orders from TSH suddenly receive ample raw material and run flat out (Zimmermann 2009). So neither end is good — it is not *less is safer*, and it is not *more is better*. The full iodine-thyroid U-curve is taught in detail on the iodine island, and the kelp story has a dedicated animation for it; go there rather than have it repeated here.
This story adds only the conclusion: your nodule almost certainly wasn't caused by iodine, and won't be dissolved by avoiding it. It is most likely what scenes 1 and 2 described — your own follicles, prodded for decades, grown uneven, and then lit up by an ultrasound with enough resolution to see them.
There are two genuine exceptions who should discuss iodine with a doctor individually: people who already test positive for Hashimoto's antibodies (details on the Hashimoto island), and people facing iodine contrast imaging or with existing hyperthyroidism.
Finally, be clear where this story lands. It does not tell you don't get checked. It tells you stratify. Anyone with a nodule should follow their own doctor and guideline-based management. This page is education about why the rules look the way they do — it is not medical advice.
See a doctor promptly, don't wait, for any of these: a persistently hoarse voice; new difficulty swallowing or breathing; a nodule that visibly enlarges over a short period; something that feels hard and fixed in place; enlarged lymph nodes in the neck; a childhood history of head-and-neck radiation; or a first-degree relative with thyroid cancer. These are signals that genuinely need pursuing — an entirely different thing from a small nodule an ultrasound stumbled onto.
数字 · 碘的 U 型曲线, 两头都不好
碘缺乏本身就是结节性甲状腺肿的经典病因, 这条链是教科书级别的因果, 不是相关性。数据也站在这一边: 把 25 项研究、5 万多人拼起来看, 尿里碘低于 100 微克每升的人, 长结节的风险比碘足够的人高约三成。但这条曲线的另一端同样要看清: 把连续剂量-反应拼起来, 整条关系是一个统计显著的 U 型 (非线性 P 值小于 0.001)——缺碘和碘过量, 两端的风险都抬高, 最低点大约落在尿碘 221 微克每升 (Lu 2026, 横断面汇总, 关联非因果)。
U 型的右半边也有机制: 碘太多的时候, 那些已经不听 thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. 指挥的自主结节会突然拿到充足原料, 立刻开足马力 (Zimmermann 2009)。所以两头都不好——既不是越少越安全, 也不是越多越好。碘和甲状腺这条 U 型曲线在碘那一岛讲得更细。
真要说例外, 只有两类人需要就碘的问题单独找医生商量: 已经查出桥本抗体的人 (细节在桥本那一岛), 以及要做碘造影或已经甲亢的人。
Debunked · six things people say
Nodules grow into cancer, so cut it out while it's smallThe vast majority of nodules are benign, and benign nodules don't turn into cancer — histologically they are two different roads. A benign nodule is scene 1's follicular structure, enlarged, still holding colloid in its centers; a cancer is a follicle cell grown distorted, no longer doing the storage job. They are not two stretches of the same road. As for the ones that really are papillary microcarcinoma, more than nine in ten don't budge in ten years (Ito 2014). The benefit of cutting early is imagined as large and the cost as zero; both are wrong.
Thyroid cancer is the lucky cancer — just take it out and you're fine
This makes two errors at once. It prices the surgical bill at zero (go back to scene 4: the recurrent laryngeal nerve and the four rice grains are pressed against the back of the gland), and it hides the genuinely dangerous minority. Scene 3 said differentiated cancer is mild because it still remembers being a follicle cell; run that backwards and the one that has entirely forgotten is savage — anaplastic carcinoma is only about 1.7% of thyroid cancers, but historical median survival is about 5 months, with 1-year survival of 20% (Bible 2021). Thyroid cancer isn't one disease; it's a group spanning a huge range of differentiation. Calling it lucky is deeply unfair to that minority.
Adding a thyroid ultrasound to the check-up package must be a good thing
Reason from mechanism first: an organ natively grained at the millimeter scale (scene 1), measured with a millimeter-scale ruler in people without symptoms — you will inevitably find a great deal, and many of those people will be pushed toward scene 4's operating table. Which is why in 2017 the US Preventive Services Task Force gave thyroid cancer screening in asymptomatic people a grade D: not recommended, because the harms outweigh the benefits (USPSTF 2017). Read the scope carefully: grade D applies to screening people without symptoms. Having symptoms, having a family history, or being told to get checked by your doctor is an entirely different situation — get checked.
Prunella or seaweed goiter pills dissolve nodules
No reliable evidence supports any herb shrinking nodules. There's a historical misunderstanding worth clearing up: classical formulas treated goiter with seaweed and kombu because ancient goiter was mostly iodine-deficiency goiter — and back then, supplying iodine meant releasing scene 2's throttle, which genuinely worked. But the nodule a check-up finds today is not the same illness at all; the old remedy is answering a different question.
Worth noting: even the pharmaceutical route isn't recommended. Guidelines explicitly advise against levothyroxine thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. suppression for benign nodules, because the benefit doesn't cover the harm (ATA 2015). If cutting the growth signal doesn't clear the bar even as a drug, an herb certainly doesn't.
Nodules come from anger and bottled-up stress
No evidence — and mechanistically there's no way in. The growth signal for follicle cells is TSH, and TSH is set by the thyroid hormone level in your blood, not by your mood. The real function of this claim isn't to explain a cause; it's to make people blame themselves, converting an anatomical finding that has nothing to do with your personality into a personal failing.
This logic only applies to the thyroid
No. But what you should take away isn't a statistical rule — it's a set of structural conditions. Any organ that meets three criteria at once will see *found* come apart from *going to harm you*:
1. It natively carries a large stock of quiet small lesions (thyroid: follicles prodded by TSH for decades)
2. Most of those lesions still do their day job and grow slowly (differentiated)
3. There is a cheap, non-invasive test whose resolution is finer than the lesions' scale (a 13 MHz probe against millimeter lumps)
With all three in place, you will find a great deal that was never going to surface. That isn't a statistical curiosity; it's the necessary consequence of those three structural conditions.
Prostate is the closest sibling: the same huge reservoir of indolent lesions, the same cheap test that pulls them up, and the same conditional, shared-decision-making recommendation from the US Preventive Services Task Force (USPSTF 2018). See the prostate island for detail.
The pattern has been quantified for thyroid cancer in women in high-income countries: an estimated 50-90% of diagnoses are overdiagnosis (Vaccarella 2016). But that number is only the scoreboard for those three structural conditions — it is not the starting point of the reasoning. The starting point is scene 1: this is simply how the organ is built.
bible-2021-ata-anaplasticuspstf-2017-thyroid-cancer-screeninguspstf-2018-psa-screeningvaccarella-2016-worldwide-overdiagnosis
References · 11
- Zimmermann, M. B. (2009). Iodine deficiency. Endocrine Reviews, 30(4), 376–408. 10.1210/er.2009-0011
- Guth, S., Theune, U., Aberle, J., Galach, A., & Bamberger, C. M. (2009). Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. European Journal of Clinical Investigation, 39(8), 699-706. 635 check-up patients: nodules in 68% with 13 MHz scanners versus 33% previously reported with 7.5 MHz. 10.1111/j.1365-2362.2009.02162.x
- Harach, H. R., Franssila, K. O., & Wasenius, V. M. (1985). Occult papillary carcinoma of the thyroid. A normal finding in Finland. A systematic autopsy study. Cancer, 56(3), 531-538. 101 autopsies sectioned at 2-3 mm; 52 occult papillary carcinoma foci in 36 glands (35.6%), the highest rate reported worldwide. pubmed.ncbi.nlm.nih.gov/2408737
- Furuya-Kanamori, L., Bell, K. J. L., Clark, J., Glasziou, P., & Doi, S. A. R. (2016). Prevalence of differentiated thyroid cancer in autopsy studies over six decades: A meta-analysis. Journal of Clinical Oncology, 34(30), 3672-3679. 35 studies, 12,834 autopsies: incidental prevalence 11.2% whole-gland vs 4.1% partial sampling; prevalence did not increase over six decades. 10.1200/JCO.2016.67.7419
- Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., et al. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26(1), 1-133. Recommends against routine TSH suppression therapy for benign nodules in iodine-sufficient populations. 10.1089/thy.2015.0020
- Ito, Y., Miyauchi, A., Kihara, M., Higashiyama, T., Kobayashi, K., & Miya, A. (2014). Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid, 24(1), 27-34. Active surveillance of 1,235 low-risk patients: 5- and 10-year enlargement 4.9% and 8.0%; no distant metastasis and no thyroid-carcinoma deaths. 10.1089/thy.2013.0367
- Oda, H., Miyauchi, A., Ito, Y., Yoshioka, K., Nakayama, A., Sasai, H., et al. (2016). Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid, 26(1), 150-155. Immediate surgery vs active surveillance: levothyroxine 66.1% vs 20.7%; permanent hypoparathyroidism 1.6% vs 0.08%. 10.1089/thy.2015.0313
- Adam, M. A., Thomas, S., Youngwirth, L., Hyslop, T., Reed, S. D., Scheri, R. P., Roman, S. A., & Sosa, J. A. (2017). Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Annals of Surgery, 265(2), 402-407. Complication likelihood decreased with increasing surgeon volume up to 26 cases per year. 10.1097/SLA.0000000000001688
- Tessler, F. N., Middleton, W. D., Grant, E. G., Hoang, J. K., Berland, L. L., Teefey, S. A., et al. (2017). ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White paper of the ACR TI-RADS Committee. Journal of the American College of Radiology, 14(5), 587-595. FNA thresholds 2.5 cm for TR3, 1.5 cm for TR4, 1.0 cm for TR5. 10.1016/j.jacr.2017.01.046
- Lu, C., Dong, H., Shi, P., Dong, W., Wen, X., & Gao, Q. (2026). Correlations between iodine status and the risk of thyroid nodules: a systematic review and dose-response meta-analysis. Frontiers in Endocrinology, 17, 1711749. 25 cross-sectional studies, 54,621 participants: nonlinear U-shaped association; iodine deficiency OR 1.28. Cross-sectional design - association, not causation. 10.3389/fendo.2026.1711749
- National Institutes of Health, Office of Dietary Supplements. (2022). Iodine — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/Iodine-HealthProfessional